Page 35 - Demo

ACARIZAX is an allergy
immunotherapy tablet.
Allergy immunotherapy works by targeting the cause of allergy.1,2
12 SQ-HDM oral lyophilisate
A NEW sublingual immunotherapy tablet that treats house dust mite allergic rhinitis and allergic asthma.1
SQ = standardised quantity. HDM = house dust mite.
PBS information: This product is not listed on the PBS
Before prescribing, please review the Product Information available
at www.seqirus.com.au/PI
MINIMUM PRODUCT INFORMATION: ACARIZAX® 12 SQ-HDM oral lyophilisate. Indications: For the treatment of adults with house dust mite (HDM) allergic rhinitis despite symptom relieving medication and/or HDM allergic asthma not well controlled by inhaled corticosteroids and associated with HDM allergic rhinitis. Patients’ asthma status should be carefully evaluated before the initiation of treatment. Contraindications: hypersensitivity to active ingredients or excipients; postpone in asthmatics with acute respiratory tract infection; FEV1 < 70% predicted value after pharmacological treatment; severe asthma exacerbation within last 3 months; autoimmune diseases, immunodeficiencies, immunosuppression or malignant neoplastic disease; acute severe oral inflammation or oral wounds. Precautions: Not a treatment for acute asthma exacerbations. Use SABA if required. Seek medical attention if asthma deteriorates. Decrease asthma medication gradually and under medical supervision. Antihistamines can be considered to manage local allergic reactions. Discontinue in the event of severe systemic allergic reactions which may be treated with adrenaline. Use adrenaline with caution in patients treated with tricyclic antidepressants, mono amino oxidase inhibitors, COMT inhibitors and beta-blockers. Postpone treatment in patients with severe oral inflammation or recent oral surgery. Use with caution if existing eosinophilic oesophagitis or autoimmune disorders in remission. Dosage and administration: 1 oral lyophilisate daily, under the tongue. Observe for 30 minutes after first dose. Do not swallow for 1 minute. Do not eat or drink for 5 minutes. Patients should have confirmed clinical history and positive test of HDM sensitisation (specific IgE and/or skin prick test). Use in children: Not recommended for use in children <18 yrs. Interactions: None identified. Adverse events: Very common; mouth oedema, oral pruritus, nasopharyngitis, throat irritation. Common; ear pruritus, oral paraesthesia, tongue pruritus, bronchitis, pharyngitis, upper respiratory infection,
asthma, laryngitis, rhinitis, sinusitis, eye pruritus, dysphonia, dyspnoea, oropharyngeal pain, pharyngeal oedema, abdominal pain, diarrhoea, dry mouth, dysphagia, dyspepsia, glossodynia, lip oedema, lip pruritus, nausea, oral discomfort, stomatitis, tongue oedema, chest discomfort. Based on Approved Product Information dated 1 August 2016. References: 1. ACARIZAX® Approved Product Information August 2016. 2. Klimek L et al. Exp Rev Clin Immunol 2016; 12: 369–77. ACARIZAX® is a registered trademark of ALK-Abelló A/S, used under licence. SeqirusTM is a trademark of Seqirus UK Limited or its affiliates. ABN 66 120 398 067. Seqirus (Australia) Pty Ltd, 63 Poplar Road, Parkville, Victoria 3052. www.seqirus.com.au. Medical Information: 1800 642 865. SEQ/ARAA/1016/0187(1). AM6804. November 2016.